Zymeworks加速药物开发,目的是提前18个月提交5份癌症治疗申请。 Zymeworks accelerates drug development, aiming to submit five cancer treatment applications 18 months early.

一家生物技术公司Zymeworks正在加速其药物开发,目的是在18个月前提交五份IND的固态肿瘤治疗申请,这要归功于它的AzytricatTM技术。 Zymeworks, a biotechnology firm, is accelerating its drug development, aiming to submit five IND applications for solid tumor treatments 18 months early, thanks to its Azymetric™ technology. 该公司在其投资组合中增加了ZW209,一种新型癌症治疗和ZW1528,一种COPD治疗。 The company has added ZW209, a novel cancer therapy, and ZW1528, a treatment for COPD, to its portfolio. 在其研发日,Zymeworks也讨论了向自发免疫和发炎疾病扩展的计划。 At its R&D Day, Zymeworks also discussed plans to expand into autoimmune and inflammatory diseases.